Ratio Analysis profitability and liquidity

2018 2017 2016 $53,647 11,179 $52,546 21,353 $52.824 7,229 159,422 63,807 171.979 69,714 171,615 80,660 $1.90 $3.57 $1.18 Financial Summary Pfizer Inc. and Subsidiary Companies (Millions, Expect 2019 per Common Share Data) Revenues $51,750 Income from 16,298 continuing operations Total Assets 167,489 Long Term 66,739 Obligations Earnings per common share- basic Income from $2.92 continuing operations attributable to Pfizer Inc. common shareholders Discontinued operations-net of tax Net income S 2.92 attributes to Pfizer Inc common shareholders Earnings per common share- diluted Income from $ 2.87 continuing operations attributable to Pfizer Inc. common shareholders Discontinued operations- net of tax Net income $2.87 attributable to Pfizer Inc. common chareholders S 1.90 $ 3.57 S 1.18 $ 1.87 lun 3.52 S 1.17 $1.87 $3.52 $1.17 (1,384) (706) 9,048 (1.122) 16.298 11,179 21,353 7.229 9 (1) 16 3 1 9 17 on income (Provision) benefit for taxes on income Income from continuing operations Income (loss) from discontinued operations, net of tax Gain (loss) on disposal of discontinued operations, net of tax Discontinued operations, net of tax Net income before allocation to noncontrolling interests Net income attributable to noncontrolling interests Net income attributable to Pfizer Inc. Preferred stock dividends, net of tax Net income attributable to Pfizer Inc. common shareholders 16,302 11,188 21,355 7.246 (29) (35) (47) (31) 16.273 11,153 21,308 7,215 (1) (1) (1) 16,272 11,152 21,307 7,214 attributable to Pfizer Inc. common shareholders Cash dividends declared per common share $1.46 $1.38 $1.30 $1.22 Source: https://www.stock-analysis-on.net/NYSE Company/Pfizer-Inc:Financial Statements 12/31/2018 12/31/2017 12/31/2016 53,647 (11,248) 42,399 (14.455) 52.546 (11,240) 41,306 (14,784) 52.824 (12,329) 40,495 (14.837) (8.006) (7.657) (7.872) (4.893) (4.758) (4,056) (1,044) (487) (1.724) Pfizer Inc- Annual Financial Report USS in millions 12 months 12/31/2019 ended: Revenues 51,750 Cost of sales (10.219) Gross profit 41,531 Selling, (14,350) informational and administrative expenses Research and (8.650) development expenses Amortization of (4,610) intangible assets Restructuring (747) charges and certain acquisition- related costs Operating 13,174 income Gain on 8,086 completion of Consumer Healthcare JV transaction Interest income 226 Interest expense (1.574) Net interest (1.348) expense Foreign currency loss related to Venezuela Royalty-related 648 income Net gains on 31 asset disposals Net gains 454 recognized 14,001 13.620 12,006 333 (1,316) (983) 391 (1.270) (879) 470 (1,186) (716) 495 499 905 71 343 171 586 648 495 499 905 31 71 343 171 454 586 (141) 168 488 (64) 288 (554) (157) (240) (510) Royalty-related income Net gains on asset disposals Net gains recognized during the period on equity securities Net realized losses on sales of investments in debt securities Income from collaborations, out-licensing arrangements and sales of compound/produ ct rights Net periodic benefit credits (costs) other than service costs Certain legal matters, net Certain asset impairments Business and legal entity alignment costs Net losses on early retirement of debt GSK Consumer Healthcare JV equity method income Other, net Other income (deductions), net Income from continuing operations before (provision) benefit for taxes on income (Provision) benefit for taxes on income Income from continuing operations (2,843) (3,115) (395) (1,447) (338) (71) (261) (138) (999) (312) 17 389 (3.578) 359 (2.116) 427 (1.315) (1,485) (3,655) 17,682 11,885 12,305 8,351 (1,384) (706) 9,048 (1.122) 16,298 11,179 21,353 7,229 Balance Sheet Breakdown By Year: 12/31/2019 12/31/2018 12/31/2017 12/31/2016 Total Assets 159,422,000 95,664,000 171,615,000 111,775,000 59,840,000 63,758,000 Total Liabilities Net Minority Interest Total Equity Gross Minority Interest Total Capitalization Preferred Stock Equity Common Stock Equity Net Tangible Assets Working Capital Invested Capital Tangible Book Value Total Debt 95,836,000 19,000 63,388,000 -25,215,000 167,489,000 104,042,000 63,447,000 99,098,000 17,000 63,126,000 -30,879,000 -4,501,000 115,271,000 -30,896,000 52, 145,000 50,840,000 9,369,000 5,534,000 171,797,000 100, 141,000 71,656,000 103,974,000 21,000 71,287,000 -33,384,000 10,714,000 113,893,000 -33,405,000 42,606,000 41,264,000 9,275,000 5,979,000 18,068,000 104,653,000 -25,234,000 41,265,000 40,126,000 9,332,000 5,717,000 90,942,000 24,000 59,520,000 -47,553,000 7,834,000 101,606,000 -47,577,000 42,086,000 39,491,000 9,230,000 6,070,000 Net Debt Share Issued Ordinary Shares Number Treasury Shares Number 3,835,000 3,615,000 3,296,000 3,160,000 2018 2017 2016 $53,647 11,179 $52,546 21,353 $52.824 7,229 159,422 63,807 171.979 69,714 171,615 80,660 $1.90 $3.57 $1.18 Financial Summary Pfizer Inc. and Subsidiary Companies (Millions, Expect 2019 per Common Share Data) Revenues $51,750 Income from 16,298 continuing operations Total Assets 167,489 Long Term 66,739 Obligations Earnings per common share- basic Income from $2.92 continuing operations attributable to Pfizer Inc. common shareholders Discontinued operations-net of tax Net income S 2.92 attributes to Pfizer Inc common shareholders Earnings per common share- diluted Income from $ 2.87 continuing operations attributable to Pfizer Inc. common shareholders Discontinued operations- net of tax Net income $2.87 attributable to Pfizer Inc. common chareholders S 1.90 $ 3.57 S 1.18 $ 1.87 lun 3.52 S 1.17 $1.87 $3.52 $1.17 (1,384) (706) 9,048 (1.122) 16.298 11,179 21,353 7.229 9 (1) 16 3 1 9 17 on income (Provision) benefit for taxes on income Income from continuing operations Income (loss) from discontinued operations, net of tax Gain (loss) on disposal of discontinued operations, net of tax Discontinued operations, net of tax Net income before allocation to noncontrolling interests Net income attributable to noncontrolling interests Net income attributable to Pfizer Inc. Preferred stock dividends, net of tax Net income attributable to Pfizer Inc. common shareholders 16,302 11,188 21,355 7.246 (29) (35) (47) (31) 16.273 11,153 21,308 7,215 (1) (1) (1) 16,272 11,152 21,307 7,214 attributable to Pfizer Inc. common shareholders Cash dividends declared per common share $1.46 $1.38 $1.30 $1.22 Source: https://www.stock-analysis-on.net/NYSE Company/Pfizer-Inc:Financial Statements 12/31/2018 12/31/2017 12/31/2016 53,647 (11,248) 42,399 (14.455) 52.546 (11,240) 41,306 (14,784) 52.824 (12,329) 40,495 (14.837) (8.006) (7.657) (7.872) (4.893) (4.758) (4,056) (1,044) (487) (1.724) Pfizer Inc- Annual Financial Report USS in millions 12 months 12/31/2019 ended: Revenues 51,750 Cost of sales (10.219) Gross profit 41,531 Selling, (14,350) informational and administrative expenses Research and (8.650) development expenses Amortization of (4,610) intangible assets Restructuring (747) charges and certain acquisition- related costs Operating 13,174 income Gain on 8,086 completion of Consumer Healthcare JV transaction Interest income 226 Interest expense (1.574) Net interest (1.348) expense Foreign currency loss related to Venezuela Royalty-related 648 income Net gains on 31 asset disposals Net gains 454 recognized 14,001 13.620 12,006 333 (1,316) (983) 391 (1.270) (879) 470 (1,186) (716) 495 499 905 71 343 171 586 648 495 499 905 31 71 343 171 454 586 (141) 168 488 (64) 288 (554) (157) (240) (510) Royalty-related income Net gains on asset disposals Net gains recognized during the period on equity securities Net realized losses on sales of investments in debt securities Income from collaborations, out-licensing arrangements and sales of compound/produ ct rights Net periodic benefit credits (costs) other than service costs Certain legal matters, net Certain asset impairments Business and legal entity alignment costs Net losses on early retirement of debt GSK Consumer Healthcare JV equity method income Other, net Other income (deductions), net Income from continuing operations before (provision) benefit for taxes on income (Provision) benefit for taxes on income Income from continuing operations (2,843) (3,115) (395) (1,447) (338) (71) (261) (138) (999) (312) 17 389 (3.578) 359 (2.116) 427 (1.315) (1,485) (3,655) 17,682 11,885 12,305 8,351 (1,384) (706) 9,048 (1.122) 16,298 11,179 21,353 7,229 Balance Sheet Breakdown By Year: 12/31/2019 12/31/2018 12/31/2017 12/31/2016 Total Assets 159,422,000 95,664,000 171,615,000 111,775,000 59,840,000 63,758,000 Total Liabilities Net Minority Interest Total Equity Gross Minority Interest Total Capitalization Preferred Stock Equity Common Stock Equity Net Tangible Assets Working Capital Invested Capital Tangible Book Value Total Debt 95,836,000 19,000 63,388,000 -25,215,000 167,489,000 104,042,000 63,447,000 99,098,000 17,000 63,126,000 -30,879,000 -4,501,000 115,271,000 -30,896,000 52, 145,000 50,840,000 9,369,000 5,534,000 171,797,000 100, 141,000 71,656,000 103,974,000 21,000 71,287,000 -33,384,000 10,714,000 113,893,000 -33,405,000 42,606,000 41,264,000 9,275,000 5,979,000 18,068,000 104,653,000 -25,234,000 41,265,000 40,126,000 9,332,000 5,717,000 90,942,000 24,000 59,520,000 -47,553,000 7,834,000 101,606,000 -47,577,000 42,086,000 39,491,000 9,230,000 6,070,000 Net Debt Share Issued Ordinary Shares Number Treasury Shares Number 3,835,000 3,615,000 3,296,000 3,160,000